MycoLogics, Inc. Moves Closer Towards The Discovery Of An Apergillus Fumigatus Vaccine
10/19/2005 5:10:27 PM
MycoLogics, Inc., an innovative biotechnology company specializing in the development of novel antifungal drugs and therapeutic and prophylactic vaccines against human fungal and parasitic pathogens, today announced award of a Phase I SBIR grant by the Department of Health and Human Services to derive a novel vaccine against Aspergillus fumigatus, a ubiquitous spore-bearing fungus that causes multiple diseases in humans. These diseases include allergic asthma, aspergillomas, and invasive pulmonary disease of those with predisposing underlying conditions.
comments powered by